Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook

Three main pillars to unlock the potential of proprietary technology platforms and intellectual property: • A proprietary non-gene editing technology platform based on multiplexing of short hairpin ribonucleic acid (shRNAs)-derived sequences to broaden the capacities of CAR-Ts • Differentiated…#belgium #celyadoncologycyad #michellussier #celyadoncology #ip #fortress #afirst #asecond #multiplex #shrnas
Source: Reuters: Health - Category: Consumer Health News Source Type: news